Press Releases May 4, 2026 04:05 PM

Silvaco Announces Participation at Upcoming Investor Conferences

Silvaco Group, Inc. to Participate in Upcoming Investor Conferences with CEO and CFO Presentations

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
SVCO

Silvaco Group, Inc., a provider of AI-enabled TCAD, EDA software, and SIP solutions for semiconductor design, announced that its CEO, Walden Rhines, and CFO, Chris Zegeralli, will participate in the Needham Technology, Media, and Consumer Conference and the B. Riley Securities 2026 Investor Conference. The company will offer live webcasts of these presentations for investors.

Silvaco Announces Participation at Upcoming Investor Conferences
SVCO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Silvaco is highlighting its AI-enabled semiconductor design and digital twin modeling solutions at major investor conferences, showcasing leadership participation.
  • The company operates across multiple semiconductor-related markets including automotive, photonics, IoT, and 5G/6G mobile technologies.
  • Silvaco maintains a global presence with offices worldwide, emphasizing its international market engagement.

SANTA CLARA, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Silvaco Group, Inc. (Nasdaq: SVCO) (“Company”, “Silvaco”), a provider of TCAD, EDA software, and SIP solutions that enable innovative semiconductor design and digital twin modeling through AI software and automation, today announced that Chief Executive Officer, Walden Rhines, and Chief Financial Officer, Chris Zegeralli, will be participating at upcoming investor conferences. Details for each event are as follows:

Event: Needham Technology, Media, and Consumer Conference
Location: Virtual
Date: Thursday, May 14
Format: Fireside chat at 9:30 a.m. Eastern time and 1x1’s

Event: B. Riley Securities 2026 Investor Conference
Location: Marina Del Rey, California
Date: Thursday, May 21
Format: 1x1’s only

A live webcast, as well as a replay, of the presentation will be available on the company’s investor relations website at https://investors.silvaco.com/.

About Silvaco

Silvaco is a provider of AI-enabled TCAD and EDA solutions, and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation. Silvaco’s solutions are used for semiconductor and photonics processes, devices, and systems development across display, power devices, automotive, memory, high performance compute, foundries, photonics, internet of things, and 5G/6G mobile markets for complex SoC design. Silvaco is headquartered in Santa Clara, California, and has a global presence with offices located in North America, Europe, Brazil, China, Egypt, Japan, Korea, Singapore, Taiwan, and Vietnam. Learn more at silvaco.com.

Safe Harbor Statement

This press release contains forward-looking statements based on Silvaco Group, Inc.'s current expectations. The words “believe”, “estimate”, “expect”, “intend”, “anticipate”, “plan”, “project”, “will”, and similar phrases as they relate to Silvaco Group, Inc. are intended to identify such forward-looking statements. These forward-looking statements reflect the current views and assumptions of Silvaco Group, Inc. and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations.

Contacts
Investor Relations:
Greg McNiff, investors@silvaco.com

Media Relations:
press@silvaco.com 


Risks

  • Forward-looking statements indicate uncertainties around future expectations and results, which may differ materially.
  • The semiconductor industry's rapid technological evolution and competitive landscape present inherent risks to Silvaco's growth.
  • Market conditions affecting technology investments could impact investor sentiment and Silvaco's financial performance.

More from Press Releases

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress Jun 14, 2026 Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026